Non-Invasive Prenatal Testing (NIPT), also known as NICC, NIPD or NIFTY (not internationally recognized), is a safe, accurate, and rapid technology for screening fetal chromosome disorders. This technique requires only a maternal blood sample and can provide extremely high accuracy in detecting conditions like Down syndrome, Edwards syndrome, Patau syndrome, and other chromosomal abnormalities (detection rate >99%). With high sequencing depth, it can also identify sex chromosome abnormalities, as well as microdeletions or microduplications on chromosomes.

Since its introduction in 2011, NIPT has gained widespread attention and recognition due to its revolutionary nature – the ability to obtain placental genetic information (representative of fetus)from maternal blood, avoiding the risks associated with invasive testing. As a result, it has become a topic of discussion and research at major international conferences, such as the International Society for Prenatal Diagnosis (ISPD) and the Fetal Medicine Foundation (FMF) World Congress. Many countries have also begun offering clinical NIPT services.

◆A CAP/LDTS dual-certified laboratory.
◆At 10 weeks of pregnancy, testing is available, along with a comprehensive support package upon confirmation.
◆Using only maternal blood screening can help avoid the associated risks of invasive testing, such as amniocentesis.
◆Whole chromosome scanning can detect conditions such as autosomal chromosomal abnormalities, sex chromosome anomalies, microdeletion disorders, and may also reveal early signs of Uniparental Disomy (UPD).
◆Testing is also available for twins, with comprehensive reports covering all testing parameters.
◆A professional genetic counseling support team assists physicians in providing more comprehensive genetic counseling to patients, reducing the workload of healthcare personnel.